Skip to main content

Drug Interactions between ivacaftor / lumacaftor and tretinoin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

tretinoin lumacaftor

Applies to: tretinoin and ivacaftor / lumacaftor

GENERALLY AVOID: Concomitant use of strong CYP450 3A4 inducers with tretinoin (systemic) may decrease the plasma concentration of tretinoin, which is a CYP450 3A4 substrate. Reduced efficacy of tretinoin may occur. Studies document the interaction between endogenous retinoids and CYP450 3A4 inducers (e.g., carbamazepine, phenytoin, phenobarbital) showing decreased concentration of the retinoids and reduced efficacy. While clinical data specific to tretinoin are not available, similar effects may occur.

MANAGEMENT: The manufacturer recommends avoiding concomitant use of tretinoin with strong CYP450 3A4 inducers due to a potentially significant reduction in its efficacy.

References (8)
  1. (2023) "Product Information. Jamp Tretinoin (tretinoin)." Jamp Pharma Corporation
  2. (2023) "Product Information. Vesanoid (tretinoin)." Neon Healthcare Ltd
  3. fex g, larsson k, andersson a, Berggren-Soderlund M (1995) "Low serum concentration of all-trans and 13-cis retinoic acids in patients treated with phenytoin, carbamazepine and valproate. Possible relation to teratogenicity" Arch Toxicol, 69, p. 572-74
  4. nau h, tzimas g, mondry m, plum c, spohr hl (1995) "Antiepileptic drugs alter endogenous retinoid concentrations: a possible mechanism of teratogenesis of anticonvulsant therapy" Life Sci, 57, p. 53-60
  5. (2024) "Product Information. Vesanoid (tretinoin)." H2-Pharma LLC
  6. (2024) "Product Information. Vesanoid (tretinoin)." Pharmaco Australia Ltd
  7. (2022) "Product Information. Vesanoid (tretinoin)." Xediton Pharmaceuticals Inc
  8. (2023) "Product Information. VESANOID (tretinoĆ­na)." CHEPLAPHARM ARZNEIMITTEL GMBH

Drug and food interactions

Moderate

ivacaftor food

Applies to: ivacaftor / lumacaftor

GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations of ivacaftor. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. Elexacaftor and tezacaftor are also CYP450 3A4 substrates in vitro and may interact similarly with grapefruit juice, whereas lumacaftor is not expected to interact.

ADJUST DOSING INTERVAL: According to prescribing information, systemic exposure to ivacaftor increased approximately 2.5- to 4-fold, systemic exposure to elexacaftor increased approximately 1.9- to 2.5-fold, and systemic exposure to lumacaftor increased approximately 2-fold following administration with fat-containing foods relative to administration in a fasting state. Tezacaftor exposure is not significantly affected by administration of fat-containing foods.

MANAGEMENT: Patients treated with ivacaftor-containing medications should avoid consumption of grapefruit juice and any food that contains grapefruit or Seville oranges. All ivacaftor-containing medications should be administered with fat-containing foods such as eggs, avocados, nuts, meat, butter, peanut butter, cheese pizza, and whole-milk dairy products. A typical cystic fibrosis diet will satisfy this requirement.

References (4)
  1. (2012) "Product Information. Kalydeco (ivacaftor)." Vertex Pharmaceuticals
  2. (2015) "Product Information. Orkambi (ivacaftor-lumacaftor)." Vertex Pharmaceuticals
  3. (2022) "Product Information. Symdeko (ivacaftor-tezacaftor)." Vertex Pharmaceuticals
  4. (2019) "Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor)." Vertex Pharmaceuticals

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.